Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

10 november 2026 uppdaterad av: University of Wisconsin, Madison

Att identifiera bördan av sjukhusvistelse på grund av Rhinovirus (RV) hos barn och mekanismer för patogenes med hjälp av luftvägsmolekylär profilering

The goal of this study is to determine the burden of Rhinoviruses (RVs) as a cause of acute, severe, respiratory illnesses leading to hospitalization. A community cohort of 120 children between 12 and 36 months of age will be enrolled in the first year of the study and followed (when well and sick) for 36 months to identify the circulating RVs and provide samples to establish a host nasal transcriptome differentiating clinical from subclinical RV infections. A hospitalized cohort of 450 infants and children will be enrolled during years 1 through 3 of the study and followed for the duration of their hospitalization to investigate the findings of the community cohort. An additional 100 healthy children aged 5-17.5 years will be enrolled for age-match comparison with the older hospitalized cohort.

Studieöversikt

Detaljerad beskrivning

Aim 1: Involves the prospective creation of a cohort of generally healthy children 12 to 36 months to be followed longitudinally for 36 months in an observational study. To determine the frequency of virus infection with RV and other respiratory viruses, children will have two swabs of the nasal mucosa performed whenever they develop an acute respiratory illness (upper respiratory symptoms lasting more than 24 hours) and four times a year for surveillance. One swab will be of the anterior nose and will be used for identification of viruses, and a second mid-turbinate swab will be used for host transcriptomics. This will allow the investigators to create many samples from both symptomatic and asymptomatic infections. The samples will be used to develop a host signature to discriminate symptomatic and asymptomatic infection.

Aim 2a: Involves the evaluation of generally healthy children hospitalized at AFCH with acute, lower respiratory tract infections including bronchiolitis, asthma, acute hypoxemic respiratory failure and community acquired pneumonia. There will also be the evaluation of infants less than 6 months of age who may become ill with an RV syndrome. These children will be evaluated with two nasal swabs as above. This allows the identification of children infected with RV and other respiratory viruses. Application of the host signature developed in Aim 1 will determine the actual proportion of those children who are infected with RV whose illness (clinical symptoms) is caused by RV.

Aim 2b: Involves the prospective creation of a cohort of generally healthy children 5 to 17.5 years old to be sampled on an as-needed basis to serve as age- and season-matched controls for the Hospitalized Group. To determine the frequency of virus infection with RV and other respiratory viruses, 2 healthy children will provide a single swab of the nasal mucosa within 2 weeks of each hospitalized participant who is 5-17.5 years of age. The one swab will be of the anterior nose and will be used for identification of viruses. Age matching will occur within 3 groups:

  • Ages 5-8 years old: n=50
  • Ages 9-13 years old: n=30
  • Ages 14-17.5 years old: n=20

Aim 3: Use parallel bulk and single cell RNA sequencing (scRNA-seq) to identify targetable processes of acute, severe LRT caused by RV. The investigators hypothesize that integrated bulk RNA-sequencing and scRNA-seq will identify immune/inflammatory defects and targets for intervention. Bulk and scRNA-seq on respiratory samples from well-characterized patients with severe RV disease will be performed to test this hypothesis and to compare samples obtained from those with non-severe disease.

Studietyp

Observationell

Inskrivning (Beräknad)

670

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Wisconsin
      • Madison, Wisconsin, Förenta staterna, 53792
        • Rekrytering
        • University of Wisconsin

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Inte äldre än 17 år (Barn)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Aim 1: Generally healthy male and female children 12 to 36 months of age living in Dane County and surrounding areas representative of the general demographics of the county.

Aim 2a: Hospitalized male and female children between newborn and 17.5 years of age with acute onset lower respiratory tract infections. These children will span all demographic and socioeconomic groups.

Aim 2b: Generally healthy male and female children 5 to 17.5 years of age living in Dane County and surrounding areas representative of the general demographics of the county.

Beskrivning

Inclusion Criteria (Aim 1 and Aim 2b Community Groups):

  • Parent/legal guardian is willing and able to provide informed consent in English.
  • Willing to comply with all study procedures and be available for the duration of the study.
  • Younger Community Group: Generally healthy children 12 to 36 months of age at the time of enrollment
  • Older Community Group: Generally healthy children 5 to 17.5 years of age at the time of enrollment.
  • Current patient within primary care system at UW Health

Inclusion Criteria (Aim 2a: Hospitalized Group):

  • Parent/legal guardian is willing and able to provide informed consent in English.
  • Admitted to American Family Children's Hospital (AFCH) within the past 24 hours or have been assigned an admission-related status (including "Admit Probable" or "IP Bed Requested") that reflects an expected inpatient admission.
  • Children under 17.5 years of age at the time of enrollment
  • Has a diagnosis of bronchiolitis, asthma exacerbation, acute hypoxemic respiratory failure or community acquired pneumonia (CAP) OR is an infant less than 6 months of age with fever greater than 38 degrees Celsius within 24 hours of hospital admission

Exclusion Criteria (all participants):

  • Congenital or currently acquired immunosuppressive condition or medications (e.g., congenital immunodeficiency, Leukemia, Lupus)
  • Congenital anomalies that might alter frequency of infection (e.g., unrepaired cleft palate, bronchial cyst, pulmonary sequestration)
  • Presence of tracheostomy or gastrostomy tube
  • Previously enrolled a different group in the study
  • Other child in the same household already enrolled in the study
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Exclusion Criteria (Aim 1: Community Group Only):

  • History of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary), reactive airway disease within the Older Community Group is not exclusionary unless they have a maintenance inhaler.
  • Acute upper respiratory symptoms within the past week (7 days) at the time of enrollment

Exclusion Criteria (Aim 2: Hospitalized Group Only):

  • History of chronic pulmonary diseases, excluding asthma (e.g., cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma is NOT exclusionary)
  • A positive test for any other respiratory virus other than RV within the 48 hours prior to and including admission documented at the time of consent. (Note: Negative for rhinovirus is not exclusionary).
  • Non-respiratory infection at the time of admission (e.g. Bacteremia) (Note: UTI, Osteomyelitis, Otitis media, and MRSA colonization is not exclusionary.)
  • Uncontrolled and/or profound neurologic disease, as determined by the investigator or designee at time of admission, considering factors such as uncontrolled seizures, inability to ambulate, inability to communicate verbally, or dependence on a gastrostomy tube (G-tube) or ventilatory assistance (e.g., positive pressure ventilation) (e.g., cerebral palsy, genetic neurologic diseases).

Exclusion Criteria (less than 5 years old only (All participants in Aim 1 and some participants in Aim 2a):

  • Born prematurely, less than 32 weeks 0 days gestational age

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Younger Community Cohort (12-36 months of age)

Quarterly Surveillance Nasal Swabs and Nasal Swabs targeted around respiratory symptoms for up to 36 months of age, participants will provide one anterior and one mid-turbinate nasal swab sample

Families will be asked to collect nasal swabs from their children during specified surveillance months (February, April, September, and December). Caregivers will be instructed to only collect surveillance samples during these months if and when children have been free of respiratory symptoms for at least two weeks prior to sampling. Caregiver surveys are part of quarterly surveillance.

Caregivers will be instructed to watch for respiratory symptoms and collect nasal swabs 24-48 hours after symptom onset. Caregiver surveys are part of sick sample collection

Caregivers are surveyed 7-13 days after sick sample collection

Hospitalized Cohort of Infants and Children

Generally healthy infants and children hospitalized for respiratory illness will provide one anterior and one mid-turbinate nasal swab sample

2 nasal swabs collected upon consent, one anterior and one mid-turbinate

For hospitalized participants who opt to induce sputum, 3 medications will be used to obtain the sample, albuterol sulfate solution and hypertonic saline (3% solution) administered via nebulizer and and lidocaine spray (4% solution) via atomizer to the nose. For hospitalized participants with pneumonia who opt for research blood draw or induced sputum, optional administration of oral sucrose (Sweet-Ease) may occur at the discretion of the treating provider.

Andra namn:
  • Hyperton koksaltlösning
  • Sweet-Ease
  • Lidokain spray
  • Albuterol sulfate solution
Older Community Cohort (5 to 17.5 years of age)

Age-matched controls for older children in the Hospitalized Group, will be called upon as needed based on enrollment of hospitalized patients

Participants will be enrolled as needed based on enrollment of hospitalized patients

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mål 1: Unikt nasalt transkriptomiskt signatur för kliniska rinovirusinfektioner
Tidsram: data insamlad upp till 36 månader
data insamlad upp till 36 månader
Aim 1: Summary of Rhinovirus Types Identified in Community Cohort
Tidsram: data collected up to 36 months

To test study hypotheses, the study team will identify the circulating RV types in symptomatic and asymptomatic children.

data collected up to 36 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Aim 2: Summary of Rhinovirus Types Identified in lower respiratory tract (LRT) infections and upper respiratory tract infections (URI), Reported as Percent in Common
Tidsram: data collected up to 36 months

To test the hypothesis that there will be an 80 percent overlap between RV types causing acute LRT and URI, investigators will compare all RV types identified in age-matched hospitalized and ambulatory children.

data collected up to 36 months
Aim 2: Proportion of Hospitalized Cohort with lower respiratory infections attributable to Rhinovirus
Tidsram: data collected up to 36 months

The investigators will use host nasal transcriptomics derived from symptomatic and asymptomatic children with RV infection to determine the proportion of age-matched hospitalized LRT infections actually attributable to RV.

data collected up to 36 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Ellen R Wald, MD, UW School of Medicine and Public Health

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

4 augusti 2026

Primärt slutförande (Beräknad)

1 maj 2030

Avslutad studie (Beräknad)

1 maj 2030

Studieregistreringsdatum

Först inskickad

13 januari 2026

Först inskickad som uppfyllde QC-kriterierna

13 januari 2026

Första postat (Faktisk)

15 januari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2025-1076
  • SMPH\PEDIATRICS\INFECT DIS (Annan identifierare: UW Madison)
  • 1R01AI182200-01A1 (U.S.S. NIH-anslag/kontrakt)
  • Protocol Version 8/25/26 (Annan identifierare: UW Madison)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

This study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-funded research that generates large-scale human or non-human genomic data, as well as the use of these data for subsequent research. Large-scale data include genome-wide association studies (GWAS), single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and gene expression data.

Tidsram för IPD-delning

Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the study team at UW-Madison.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera